Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.
Identifieur interne : 000466 ( PubMed/Curation ); précédent : 000465; suivant : 000467Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.
Auteurs : Hye Won Kwak [Corée du Sud] ; Hyo-Jung Park [Corée du Sud] ; Hae Li Ko [Corée du Sud] ; Hyelim Park [Corée du Sud] ; Min Ho Cha [Corée du Sud] ; Sang-Myeong Lee [Corée du Sud] ; Kyung Won Kang [Corée du Sud] ; Rhoon-Ho Kim [Corée du Sud] ; Seung Rok Ryu [Corée du Sud] ; Hye-Jung Kim [Corée du Sud] ; Jae-Ouk Kim [Corée du Sud] ; Manki Song [Corée du Sud] ; Hun Kim [Corée du Sud] ; Dae Gwin Jeong [Corée du Sud] ; Eui-Cheol Shin [Corée du Sud] ; Jae-Hwan Nam [Corée du Sud]Source :
- Vaccine [ 1873-2518 ] ; 2019.
Abstract
An ideal adjuvant should increase vaccine efficacy through balanced Th1/Th2 responses and be safe to use. Recombinant protein-based vaccines are usually formulated with aluminum (alum)-based adjuvants to ensure an adequate immune response. However, use of alum triggers a Th2-biased immune induction, and hence is not optimal. Although the adjuvanticity of RNA has been reported, a systematic and overall investigation on its efficacy is lacking. We found that single strand RNA (termed RNA adjuvant) derived from cricket paralysis virus intergenic region internal ribosome entry site induced the expression of various adjuvant-function-related genes, such as type 1 and 2 interferon (IFN) and toll-like receptor (TLR), T cell activation, and leukocyte chemotaxis in human peripheral blood mononuclear cells; furthermore, its innate and IFN transcriptome profile patterns were similar to those of a live-attenuated yellow fever vaccine. This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. Application of the RNA adjuvant in mouse enhanced the efficacy of Middle East respiratory syndrome spike protein, a protein-subunit vaccine and human papillomavirus L1 protein, a virus-like particle vaccine, by activating innate immune response through TLR7 and enhancing pAPC chemotaxis, leading to a balanced Th1/Th2 responses. Moreover, the combination of alum and the RNA adjuvant synergistically induced humoral and cellular immune responses and endowed long-term immunity. Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.
DOI: 10.1016/j.vaccine.2019.07.070
PubMed: 31371226
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000466
Links to Exploration step
pubmed:31371226Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.</title>
<author><name sortKey="Kwak, Hye Won" sort="Kwak, Hye Won" uniqKey="Kwak H" first="Hye Won" last="Kwak">Hye Won Kwak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hyo Jung" sort="Park, Hyo Jung" uniqKey="Park H" first="Hyo-Jung" last="Park">Hyo-Jung Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ko, Hae Li" sort="Ko, Hae Li" uniqKey="Ko H" first="Hae Li" last="Ko">Hae Li Ko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hyelim" sort="Park, Hyelim" uniqKey="Park H" first="Hyelim" last="Park">Hyelim Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cha, Min Ho" sort="Cha, Min Ho" uniqKey="Cha M" first="Min Ho" last="Cha">Min Ho Cha</name>
<affiliation wicri:level="1"><nlm:affiliation>KM Application Center, Korea Institute of Oriental Medicine, Daegu, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>KM Application Center, Korea Institute of Oriental Medicine, Daegu</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Sang Myeong" sort="Lee, Sang Myeong" uniqKey="Lee S" first="Sang-Myeong" last="Lee">Sang-Myeong Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kang, Kyung Won" sort="Kang, Kyung Won" uniqKey="Kang K" first="Kyung Won" last="Kang">Kyung Won Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Rhoon Ho" sort="Kim, Rhoon Ho" uniqKey="Kim R" first="Rhoon-Ho" last="Kim">Rhoon-Ho Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ryu, Seung Rok" sort="Ryu, Seung Rok" uniqKey="Ryu S" first="Seung Rok" last="Ryu">Seung Rok Ryu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hye Jung" sort="Kim, Hye Jung" uniqKey="Kim H" first="Hye-Jung" last="Kim">Hye-Jung Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Song, Manki" sort="Song, Manki" uniqKey="Song M" first="Manki" last="Song">Manki Song</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Life Science Research Institute, SK Bioscience, Seongnam, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Life Science Research Institute, SK Bioscience, Seongnam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jeong, Dae Gwin" sort="Jeong, Dae Gwin" uniqKey="Jeong D" first="Dae Gwin" last="Jeong">Dae Gwin Jeong</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shin, Eui Cheol" sort="Shin, Eui Cheol" uniqKey="Shin E" first="Eui-Cheol" last="Shin">Eui-Cheol Shin</name>
<affiliation wicri:level="1"><nlm:affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nam, Jae Hwan" sort="Nam, Jae Hwan" uniqKey="Nam J" first="Jae-Hwan" last="Nam">Jae-Hwan Nam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31371226</idno>
<idno type="pmid">31371226</idno>
<idno type="doi">10.1016/j.vaccine.2019.07.070</idno>
<idno type="wicri:Area/PubMed/Corpus">000466</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000466</idno>
<idno type="wicri:Area/PubMed/Curation">000466</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000466</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.</title>
<author><name sortKey="Kwak, Hye Won" sort="Kwak, Hye Won" uniqKey="Kwak H" first="Hye Won" last="Kwak">Hye Won Kwak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hyo Jung" sort="Park, Hyo Jung" uniqKey="Park H" first="Hyo-Jung" last="Park">Hyo-Jung Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ko, Hae Li" sort="Ko, Hae Li" uniqKey="Ko H" first="Hae Li" last="Ko">Hae Li Ko</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Park, Hyelim" sort="Park, Hyelim" uniqKey="Park H" first="Hyelim" last="Park">Hyelim Park</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cha, Min Ho" sort="Cha, Min Ho" uniqKey="Cha M" first="Min Ho" last="Cha">Min Ho Cha</name>
<affiliation wicri:level="1"><nlm:affiliation>KM Application Center, Korea Institute of Oriental Medicine, Daegu, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>KM Application Center, Korea Institute of Oriental Medicine, Daegu</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Sang Myeong" sort="Lee, Sang Myeong" uniqKey="Lee S" first="Sang-Myeong" last="Lee">Sang-Myeong Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kang, Kyung Won" sort="Kang, Kyung Won" uniqKey="Kang K" first="Kyung Won" last="Kang">Kyung Won Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Rhoon Ho" sort="Kim, Rhoon Ho" uniqKey="Kim R" first="Rhoon-Ho" last="Kim">Rhoon-Ho Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ryu, Seung Rok" sort="Ryu, Seung Rok" uniqKey="Ryu S" first="Seung Rok" last="Ryu">Seung Rok Ryu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Division of Biotechnology, The Chonbuk National University, Iksan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hye Jung" sort="Kim, Hye Jung" uniqKey="Kim H" first="Hye-Jung" last="Kim">Hye-Jung Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Jae Ouk" sort="Kim, Jae Ouk" uniqKey="Kim J" first="Jae-Ouk" last="Kim">Jae-Ouk Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Song, Manki" sort="Song, Manki" uniqKey="Song M" first="Manki" last="Song">Manki Song</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name>
<affiliation wicri:level="1"><nlm:affiliation>Life Science Research Institute, SK Bioscience, Seongnam, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Life Science Research Institute, SK Bioscience, Seongnam</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jeong, Dae Gwin" sort="Jeong, Dae Gwin" uniqKey="Jeong D" first="Dae Gwin" last="Jeong">Dae Gwin Jeong</name>
<affiliation wicri:level="1"><nlm:affiliation>Infectious Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Infectious Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shin, Eui Cheol" sort="Shin, Eui Cheol" uniqKey="Shin E" first="Eui-Cheol" last="Shin">Eui-Cheol Shin</name>
<affiliation wicri:level="1"><nlm:affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nam, Jae Hwan" sort="Nam, Jae Hwan" uniqKey="Nam J" first="Jae-Hwan" last="Nam">Jae-Hwan Nam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Biotechnology, The Catholic University of Korea, Bucheon</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An ideal adjuvant should increase vaccine efficacy through balanced Th1/Th2 responses and be safe to use. Recombinant protein-based vaccines are usually formulated with aluminum (alum)-based adjuvants to ensure an adequate immune response. However, use of alum triggers a Th2-biased immune induction, and hence is not optimal. Although the adjuvanticity of RNA has been reported, a systematic and overall investigation on its efficacy is lacking. We found that single strand RNA (termed RNA adjuvant) derived from cricket paralysis virus intergenic region internal ribosome entry site induced the expression of various adjuvant-function-related genes, such as type 1 and 2 interferon (IFN) and toll-like receptor (TLR), T cell activation, and leukocyte chemotaxis in human peripheral blood mononuclear cells; furthermore, its innate and IFN transcriptome profile patterns were similar to those of a live-attenuated yellow fever vaccine. This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. Application of the RNA adjuvant in mouse enhanced the efficacy of Middle East respiratory syndrome spike protein, a protein-subunit vaccine and human papillomavirus L1 protein, a virus-like particle vaccine, by activating innate immune response through TLR7 and enhancing pAPC chemotaxis, leading to a balanced Th1/Th2 responses. Moreover, the combination of alum and the RNA adjuvant synergistically induced humoral and cellular immune responses and endowed long-term immunity. Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">31371226</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>37</Volume>
<Issue>36</Issue>
<PubDate><Year>2019</Year>
<Month>Aug</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.</ArticleTitle>
<Pagination><MedlinePgn>5191-5202</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(19)30991-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2019.07.070</ELocationID>
<Abstract><AbstractText>An ideal adjuvant should increase vaccine efficacy through balanced Th1/Th2 responses and be safe to use. Recombinant protein-based vaccines are usually formulated with aluminum (alum)-based adjuvants to ensure an adequate immune response. However, use of alum triggers a Th2-biased immune induction, and hence is not optimal. Although the adjuvanticity of RNA has been reported, a systematic and overall investigation on its efficacy is lacking. We found that single strand RNA (termed RNA adjuvant) derived from cricket paralysis virus intergenic region internal ribosome entry site induced the expression of various adjuvant-function-related genes, such as type 1 and 2 interferon (IFN) and toll-like receptor (TLR), T cell activation, and leukocyte chemotaxis in human peripheral blood mononuclear cells; furthermore, its innate and IFN transcriptome profile patterns were similar to those of a live-attenuated yellow fever vaccine. This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. Application of the RNA adjuvant in mouse enhanced the efficacy of Middle East respiratory syndrome spike protein, a protein-subunit vaccine and human papillomavirus L1 protein, a virus-like particle vaccine, by activating innate immune response through TLR7 and enhancing pAPC chemotaxis, leading to a balanced Th1/Th2 responses. Moreover, the combination of alum and the RNA adjuvant synergistically induced humoral and cellular immune responses and endowed long-term immunity. Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.</AbstractText>
<CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwak</LastName>
<ForeName>Hye Won</ForeName>
<Initials>HW</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Hyo-Jung</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ko</LastName>
<ForeName>Hae Li</ForeName>
<Initials>HL</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Park</LastName>
<ForeName>Hyelim</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cha</LastName>
<ForeName>Min Ho</ForeName>
<Initials>MH</Initials>
<AffiliationInfo><Affiliation>KM Application Center, Korea Institute of Oriental Medicine, Daegu, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Sang-Myeong</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>Kyung Won</ForeName>
<Initials>KW</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Rhoon-Ho</ForeName>
<Initials>RH</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ryu</LastName>
<ForeName>Seung Rok</ForeName>
<Initials>SR</Initials>
<AffiliationInfo><Affiliation>Division of Biotechnology, The Chonbuk National University, Iksan, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hye-Jung</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Jae-Ouk</ForeName>
<Initials>JO</Initials>
<AffiliationInfo><Affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Song</LastName>
<ForeName>Manki</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Clinical Research Lab, International Vaccine Institute, Seoul National University Research Park, Seoul, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kim</LastName>
<ForeName>Hun</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Life Science Research Institute, SK Bioscience, Seongnam, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jeong</LastName>
<ForeName>Dae Gwin</ForeName>
<Initials>DG</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shin</LastName>
<ForeName>Eui-Cheol</ForeName>
<Initials>EC</Initials>
<AffiliationInfo><Affiliation>Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nam</LastName>
<ForeName>Jae-Hwan</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea. Electronic address: jhnam@catholic.ac.kr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvant</Keyword>
<Keyword MajorTopicYN="N">Alum</Keyword>
<Keyword MajorTopicYN="N">CrPV</Keyword>
<Keyword MajorTopicYN="N">HPV</Keyword>
<Keyword MajorTopicYN="N">IRES</Keyword>
<Keyword MajorTopicYN="N">MERS</Keyword>
<Keyword MajorTopicYN="N">RNA</Keyword>
<Keyword MajorTopicYN="N">Th1/Th2</Keyword>
<Keyword MajorTopicYN="N">Vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>05</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>06</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>07</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31371226</ArticleId>
<ArticleId IdType="pii">S0264-410X(19)30991-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2019.07.070</ArticleId>
<ArticleId IdType="pmc">PMC7115557</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2013 Feb;87(3):1290-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23175362</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2008 Apr;7(3):373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18393607</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2011 Apr 12;29(17):3341-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20713100</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunother. 2011 Jan;34(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21150709</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Microbiol Biotechnol. 2019 Jan 28;29(1):127-140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30518020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Immunol. 2009 Jan;10(1):116-125</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19029902</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Immunol. 2018 Apr 26;36:667-694</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29677479</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2014 Jun 15;192(12):5459-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24907379</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2006 May 1;193(9):1323-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16586371</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Immunol. 2009 Apr;9(4):287-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19247370</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2015 May;479-480:379-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25864107</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2016 Apr 14;90(9):4278-4288</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26865713</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 1970 Oct;122(4):339-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4323444</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2015;11(2):477-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25692535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2015 Mar;14(3):447-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25308798</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Rev. 2011 Jan;239(1):178-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21198672</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Oncologist. 2008 Aug;13(8):859-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18701762</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Pharm. 2014 Oct 6;11(10):3395-408</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25157701</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2008 Dec 22;205(13):3119-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19047440</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Semin Immunol. 2018 Oct;39:14-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29801750</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2011 Nov 21;208(12):2357-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22065672</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cancer Res. 2015 Dec 15;75(24):5187-5193</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26627006</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2011 Jul 30;378(9789):428-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21664680</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Immunol. 2017 Aug;47:44-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28734174</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2015 Apr;89(7):3659-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589660</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2016 Jan 1;196(1):310-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26590319</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Immunol. 2009 Apr;46(7):1443-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19181387</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2017 Feb 15;198(4):1595-1605</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28077601</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS One. 2014 Jul 07;9(7):e101576</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24999962</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cytokine Growth Factor Rev. 2016 Oct;31:1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27185365</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2016 Oct 2;12(10):2709-2711</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27551808</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Front Immunol. 2013 May 16;4:114</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23720661</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Invest. 2010 May;120(5):1674-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20389020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2005 Nov 7;202(9):1179-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16260489</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Invest. 2016 Mar 1;126(3):799-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26928033</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Invest. 2002 May;109(10):1271-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12021240</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Drug Deliv Rev. 2013 Oct;65(10):1386-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23751781</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Med. 2018 Jun 4;215(6):1571-1588</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29739835</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000466 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000466 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:31371226 |texte= Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31371226" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |